While single-agent therapies targeting oncogenic pathways are often only modestly effective against ER+ breast tumors, combination treatment with anti-estrogens is frequently more effective than anti-estrogens alone [36, 37]. This evidence concerns the gene ESR1 and breast neoplasm.